September 30, 2025

Single Dose of Radiation as Effective as 5-Week Course for Lung Cancer: Roswell Park Shares Results at ASTRO

Dr. Mark Farrugia describes new approach to post-operative radiation therapy for non-small cell lung cancer

Roswell Park Comprehensive Cancer Center

September 22, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

September 18, 2025

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cel...

The ASCO Post

September 15, 2025

Study Led by Roswell Park’s Dr. Sai Yendamuri Finds GLP-1 Receptor Agonists Improve Lung Cancer Outcomes

Lung cancer patients who take medications called GLP-1 receptor agonists — commonly prescribed for weight loss and diabetes management — fare better than those who don’t, according to research.

Roswell Park Comprehensive Cancer Center

September 15, 2025

ctDNA May Guide Immunotherapy in Limited-Stage SCLC

“This is the first study to show that early ctDNA detection after induction chemotherapy can help identify patients who are more likely to benefit from consolidation immunotherapy.... It’s a step towa...

The ASCO Post

September 12, 2025

STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach

The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC) whether undergoing segmentectomy ...

The ASCO Post

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

February 08, 2023

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been as...

The ASCO Post

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post